Atherosclerotic Cardiovascular Disease (ASCVD)SPARK-CVDNCT06589791
A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists
An observational study of Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD), run by Novo Nordisk A/S at 1 site in China.
Trial summary
This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- What is being tested?
- No treatment given
- How many people
- 1,500 participants
- Where
- 1 siteChina
- Study dates
- 9 Sep 2024to 5 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cardiologists and nephrologists with patients that have ASCVD and CKD in China
Who may be able to join
- Work in cardiology, internal medicine, or nephrology department
- Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
- Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
- Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month
Who cannot join
- Unwilling to provide informed consent
- Insufficient number of patients with ASCVD and CKD
- Do not fulfil inclusion criteria.
Trial locations and contacts
1 site in 1 country.
About this study
This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting.
- Being tested
- No treatment given
- Medical subject headings
- Atherosclerosis, Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
Online self-completion survey
| Study group | Role | What they receive |
|---|---|---|
| Health care professionals | Cardiologists and nephrologists in China Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Health care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD
Multi-select from a defined list; Single-select from a defined list; Numerical; 7-point Likert scale for measurement of agreement to different statements from 1 "strongly disagree" to 7 "strongly agree"
Measured: At the time of survey response (Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start9 Sep 2024
- Primary completion5 Dec 2024
- Study completion5 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atherosclerotic Cardiovascular Disease (ASCVD)Studies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency dept. 2834, Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06589791
- Sponsor's protocol ID
- DAS-8091
- Other IDs
- U1111-1303-3098
- Acronym
- SPARK-CVD
- Status last verified
- Nov 2025
- First submitted
- 6 Sep 2024
- Last updated
- 5 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists
- ClinicalTrials.gov ID
- NCT06589791
- Acronym / sponsor ID
- SPARK-CVD / DAS-8091
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,500 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 9 Sep 2024 (actual)
- Primary completion
- 5 Dec 2024 (actual)
- Study completion
- 5 Dec 2024 (actual)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Health care professionals | – | Other: No treatment givenCardiologists and nephrologists in China |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cardiologists and nephrologists with patients that have ASCVD and CKD in China
Key inclusion criteria (4 listed)
- Work in cardiology, internal medicine, or nephrology department
- Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
- Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
- Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month
Key exclusion criteria (3 listed)
- Unwilling to provide informed consent
- Insufficient number of patients with ASCVD and CKD
- Do not fulfil inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No treatment givenOnline self-completion survey | Other | Health care professionals |
Primary outcome
Health care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD
Time frame: At the time of survey response (Day 1)
Multi-select from a defined list; Single-select from a defined list; Numerical; 7-point Likert scale for measurement of agreement to different statements from 1 "strongly disagree" to 7 "strongly agree"
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2025.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Atherosclerotic Cardiovascular Disease (ASCVD)
Active, not recruitingPhase 2
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Lipoprotein Disorder
Active, not recruitingPhase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Atherosclerotic Cardiovascular Disease
Not yet recruitingPhase 2
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
Recruiting
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
ASCVD, LDL-C
Active, not recruitingPhase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency dept. 2834 study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD), run by Novo Nordisk A/S at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Health care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD (time frame: At the time of survey response (Day 1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2025.